CoChat

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial

Chiron, C, Marchand, MC, Tran, A, Rey, E, d'Athis, P, Vincent, J, Dulac, O, Pons, G · 2000 · The Lancet

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Background Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial. Methods After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. Patients then received stiripentol in an open fashion. Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic-clonic) seizures during the second month of the double-blind period compared with baseline. Findings 15 (71%) patients were responders on stiripentol (including nine free of clonic or tonic-clonic seizures), whereas there was only one (5%) on placebo (none were seizure free; stiripentol 95% CI 52.1-90.7 vs placebo 0-14.6). The 95% CI of the difference was 42.2-85.7. Percentage of change from baseline was higher on stiripentol (-69%) than on placebo (+7%), p Interpretation This controlled trial shows the antiepileptic efficacy, of add-on stiripentol in children with SMEI. The results also provide good reason to focus studies on a specific epilepsy syndrome-a small sample of patients is sufficient to show the efficacy that might have been missed in a heterogeneous population.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(00)03157-3

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 3

  1. Peters, 1996, Vigabatrin as first-line monotherapy in newly diagnosed infantile spasms: a placebocontrolled double-blind study, Epilepsia, 37, 118
  2. Elterman, 1997, Topiramate YP study team. A double-blind trial of topiramate in partial seizures in children, Epilepsia, 38, S131
  3. Levy, 1987, Effect of stiripentol on valproate plasma concentration and metabolism, Epilepsia, 28, 605

Cited by

See all 573

Metadata

Authors
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G.
Affiliations
  • Inserm (FR)
  • Hôpital Saint-Vincent-de-Paul (FR)
Corresponding author
Chiron, C
Venue
The Lancet
Publisher
Elsevier BV
Published
2000-11
Volume
356
Issue
9242
Pages
1638-1642
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2101383744
Cited by
568
References
25
Citations by year
2026: 15 · 2025: 29 · 2024: 30 · 2023: 27 · 2022: 24 · 2021: 32 · 2020: 30 · 2019: 44 · 2018: 20 · 2017: 23 · 2016: 20 · 2015: 26 · 2014: 27 · 2013: 29 · 2012: 26
FWCI
6.55
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
stiripentol, Dravet syndrome, antiepileptic drug efficacy, adjunctive therapy, valproic acid, clobazam, seizure frequency reduction, pediatric epilepsy, adverse drug reactions
MeSH terms
Clobazam, Anticonvulsants, Benzodiazepines, Child, Preschool, Dioxolanes, Double-Blind Method, Drug Therapy, Combination, Epilepsies, Myoclonic, Female, Humans, Infant, Male, Syndrome, Anti-Anxiety Agents, Valproic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. https://app.cochat.ai/papers/10.1016/s0140-6736(00)03157-3
The paper
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000). Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. The Lancet. https://doi.org/10.1016/s0140-6736(00)03157-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.